Latest Sofinnova Investments, Inc. Stock Portfolio

Sofinnova Investments, Inc. Performance:

2025 Q4: 28.99%YTD: 43.58%2024: 8.13%

Performance for 2025 Q4 is 28.99%, and YTD is 43.58%, and 2024 is 8.13%.

About Sofinnova Investments, Inc. and 13F Hedge Fund Stock Holdings

On 2026-02-13, the fund reported it's updated stock portfolio. In the 13F Holdings report, Sofinnova Investments, Inc. reported an equity portfolio of $2.3 Billions as of 31 Dec, 2025.

The top stock holdings of Sofinnova Investments, Inc. are NTRA, JAZZ, AZN. The fund has invested 15.3% of it's portfolio in NATERA INC and 7% of portfolio in JAZZ PHARMACEUTICALS PLC.

The fund managers got completely rid off GILEAD SCIENCES INC (GILD), BOSTON SCIENTIFIC CORP (BSX) and AKERO THERAPEUTICS INC (AKRO) stocks. They significantly reduced their stock positions in AXSOME THERAPEUTICS INC (AXSM), SOLENO THERAPEUTICS INC (SLNO) and SAVARA INC (SVRA). Sofinnova Investments, Inc. opened new stock positions in BRISTOL-MYERS SQUIBB CO (BMY), ELI LILLY & CO (LLY) and BIOMARIN PHARMACEUTICAL INC (BMRN). The fund showed a lot of confidence in some stocks as they added substantially to DISC MEDICINE INC, IMMUNOME INC (IMNM) and NEKTAR THERAPEUTICS (NKTR).

Sofinnova Investments, Inc. Annual Return Estimates Vs S&P 500

Our best estimate is that Sofinnova Investments, Inc. made a return of 28.99% in the last quarter. In trailing 12 months, it's portfolio return was 43.58%.

Performance
S&P 500

New Buys

Ticker	$ Bought
bristol-myers squibb co	81,610,900
eli lilly & co	66,256,200
biomarin pharmaceutical inc	41,430,600
centessa pharmaceuticals plc	27,617,900
alcon ag	26,205,900
amylyx pharmaceuticals inc	6,367,360
masimo corp	6,008,900
xenon pharmaceuticals inc	2,684,720

New stocks bought by Sofinnova Investments, Inc.

Additions

Ticker	% Inc.
disc medicine inc	719
immunome inc	271
nektar therapeutics	270
cidara therapeutics inc	232
establishment labs hldgs inc	162
acadia pharmaceuticals inc	144
dyne therapeutics inc	128
abbvie inc	110

Additions to existing portfolio by Sofinnova Investments, Inc.

Reductions

Ticker	% Reduced
axsome therapeutics inc	-96.88
soleno therapeutics inc	-92.53
savara inc	-87.45
roivant sciences ltd	-76.67
exact sciences corp	-72.21
dexcom inc	-51.49
praxis precision medicines inc	-27.26
united therapeutics corp	-17.3

Sofinnova Investments, Inc. reduced stake in above stock

Sold off

Ticker	$ Sold
gilead sciences inc	-139,007,000
boston scientific corp	-55,593,200
akero therapeutics inc	-22,487,700
ptc therapeutics inc	-11,472,000
merus n v	-15,697,500
scholar rock hldg corp	-1,169,710

Sofinnova Investments, Inc. got rid off the above stocks

Sector Distribution

Sofinnova Investments, Inc. has about 80.3% of it's holdings in Healthcare sector.

Sector	%
Healthcare	80.3
Others	19.7

Market Cap. Distribution

Sofinnova Investments, Inc. has about 51.4% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
LARGE-CAP	45.4
MID-CAP	26
UNALLOCATED	19.7
MEGA-CAP	6
SMALL-CAP	2.8

Stocks belong to which Index?

About 44% of the stocks held by Sofinnova Investments, Inc. either belong to S&P 500 or RUSSELL 2000 index.

Index	%
Others	56
RUSSELL 2000	27.1
S&P 500	16.9

Top 5 Winners (%)		%
PRAX	praxis precision medicines inc	393.9 %
NXTC	nextcure inc	142.2 %
COGT	cogent biosciences inc	142.0 %
	inhibrx biosciences inc	129.6 %
WVE	wave life sciences ltd	127.3 %

Top 5 Winners ($)		$
NTRA	natera inc	105.6 M
VERA	vera therapeutics inc	60.3 M
COGT	cogent biosciences inc	43.4 M
PRAX	praxis precision medicines inc	36.1 M
JAZZ	jazz pharmaceuticals plc	29.6 M

Top 5 Losers (%)		%
QURE	uniqure nv	-56.1 %
NKTR	nektar therapeutics	-18.0 %
SLNO	soleno therapeutics inc	-16.9 %
IKNA	imagenebio inc	-15.3 %
DXCM	dexcom inc	-1.0 %

Top 5 Losers ($)		$
QURE	uniqure nv	-5.4 M
NKTR	nektar therapeutics	-4.1 M
SLNO	soleno therapeutics inc	-1.9 M
ABBV	abbvie inc	-0.7 M
DXCM	dexcom inc	-0.5 M

Sofinnova Investments, Inc. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Sofinnova Investments, Inc.

Sofinnova Investments, Inc. has 60 stocks in it's portfolio. About 54.2% of the portfolio is in top 10 stocks. QURE proved to be the most loss making stock for the portfolio. NTRA was the most profitable stock for Sofinnova Investments, Inc. last quarter.

Last Reported on: 13 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ABBV	abbvie inc	3.13	317,783	72,610,200	added	110

ACAD	acadia pharmaceuticals inc	0.08	65,567	1,751,300	added	144

AKRO	akero therapeutics inc	0.00	0.00	0.00	sold off	-100

ALC	alcon ag	1.13	332,520	26,205,900	new

AMLX	amylyx pharmaceuticals inc	0.28	527,099	6,367,360	new

ANAB	anaptysbio inc	0.60	287,690	13,947,200	added	13.14

AVTE	jade biosciences inc	0.07	107,391	1,657,040	unchanged	0.00

AXSM	axsome therapeutics inc	0.10	12,266	2,240,260	reduced	-96.88

AZN	astrazeneca plc	6.47	1,632,330	150,060,000	added	98.11

BBIO	bridgebio pharma inc	2.38	720,448	55,107,100	reduced	-13.39

BMRN	biomarin pharmaceutical inc	1.79	697,133	41,430,600	new

BMY	bristol-myers squibb co	3.52	1,512,990	81,610,900	new

BOLT	bolt biotherapeutics inc	0.03	137,721	753,058	unchanged	0.00

BSX	boston scientific corp	0.00	0.00	0.00	sold off	-100

CDTX	cidara therapeutics inc	1.72	180,265	39,818,700	added	232

CELC	celcuity inc	1.29	299,417	29,863,900	added	18.17

CMPX	compass therapeutics inc	0.78	3,365,450	18,072,400	added	65.88

CNTA	centessa pharmaceuticals plc	1.19	1,104,270	27,617,900	new

COGT	cogent biosciences inc	3.02	1,973,620	70,103,200	reduced	-7.25

DXCM	dexcom inc	1.08	378,219	25,102,400	reduced	-51.49